Radical Cystectomy (RC) remains the gold standard for localized muscle-invasive bladder cancer (MIBC); however, use of ureteral stents at time of surgery remains controversial without level 1 evidence to comment on risks or benefits of their use. RC complications commonly include urinary tract infections (UTIs), pyelonephritis, ureteroileal leakage and stenosis, and can occur with either ileal conduit or orthotopic neobladder diversions. Traditionally, ureteral stents are thought to support anastomotic healing and reduce the risk of anastomotic leakage and strictures; however, emerging evidence from retrospective studies suggests that stent use may paradoxically increase rates of postoperative morbidity. This randomized, multicenter and prospective study aims to compare 30-day postoperative complication rates between stented and non-stented urinary diversions in patients undergoing RC for MIBC, in both ileal conduit or neobladder with either robotic or open approaches.
Radical Cystectomy (RC) remains the gold standard for localized muscle-invasive bladder cancer (MIBC); however, use of ureteral stents at time of surgery remains controversial without level 1 evidence to comment on risks or benefits of their use. RC complications commonly include urinary tract infections (UTIs), pyelonephritis, ureteroileal leakage and stenosis, and can occur with either ileal conduit or orthotopic neobladder diversions. Traditionally, ureteral stents are thought to support anastomotic healing and reduce the risk of anastomotic leakage and strictures; however, emerging evidence from retrospective studies suggests that stent use may paradoxically increase rates of postoperative morbidity. This randomized, multicenter and prospective study aims to compare 30-day postoperative complication rates between stented and non-stented urinary diversions in patients undergoing RC for MIBC, in both ileal conduit or neobladder with either robotic or open approaches. Randomization between ureteroenteric anastomosis with or without ureteral stent placement will occur at time of surgery; the surgeon will know this information at time of surgery and the patient will be aware of the placement of stents following surgery as these are externalized and visible. The primary outcome will be complication rate in 30 days after the surgery. Secondary outcomes of this trial will include: length of stay, procedure duration, emergency room visits, patient reported pain, anastomotic leakage rate, ureteral stricture rate, post-operative nephrostomy tube placement, differences in complication rates between interrupted and running suture technique. The study will be conducted across three academic institutions: Brigham and Women's Hospital (BWH), Massachusetts General Hospital (MGH) and Instituto do Câncer do Estado de São Paulo (ICESP), Brazil.
standard of care single-J externalized ureteral stents to be placed at time of radical cystectomy
no ureteral stents used at time of radical cystectomy
Brigham and Women's Hospital
Boston, Massachusetts, United States
Instituto do Câncer do Estado de São Paulo (ICESP)
São Paulo, São Paulo, Brazil
Post-operative readmission rate
percent of patients re-admitted
Time frame: 30-days after surgery
length of stay
index hospitalization (days after surgery until discharge, excluding pre-admission if applicable)
Time frame: 30 days
procedure duration
surgical time measured from incision to closing
Time frame: 30 days
blood transfusion rate
percent of patients requiring blood transfusion
Time frame: 30 days
Emergency room visits
percent of patients presenting to emergency room at least once after surgery
Time frame: 30 days
patient reported pain on analog scale
analog 0 to 10 scale where 0 is no pain (best) and 10 is excruciating pain (worst)
Time frame: 30 days
ureteral stricture rate
percent of patients developing ureteral stricture requiring intervention (e.g. nephrostomy tube placement)
Time frame: 30 days
urine leak rate
percent of patients developing urine leak requiring intervention (e.g. interventional radiology procedure)
Time frame: 30 days
pyelonephritis rate
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
percent of patients developing of urinary tract infection (defined by clinical sequelae of infection in setting of positive urinalysis requiring treatment with antibiotics)
Time frame: 30 days